In another study by Gangadhara et al. [60], the drug response to endocrine agents (tamoxifen, fulvestrant) and trastuzumab was assessed for ER-positive/HER2-positive breast cancer 2D and 3D models. Here, ERBB2 is linked to breast carcinoma.